Can intestinal bacteria help us fight tumors? Promises and limits of research

In the intestine, certain microorganisms transform fibers into substances that nourish cells and support their defenses. Among these, butyrate stands out. Three scientific reviews explore its potential role in colorectal tumors. The story is promising, but the decisive step is still missing: demonstrating what benefits it can offer to patients.

Introduction

A patient preparing for surgery for a colon tumor may have many questions. One concerns an everyday matter: can what happens in the intestine help in coping with the disease? And can the bacteria that inhabit it become allies?

Research is exploring this possibility. However, helping the intestine function better does not necessarily mean stopping a tumor.

The starting point is the intestinal microbiota: the community of microorganisms that lives within us. We can imagine it as a neighborhood with diverse, interconnected activities. Some inhabitants transform dietary fibers that we cannot digest into substances that our cells can use.

One of these substances is butyrate, which certain bacteria produce naturally in the intestine when they metabolize dietary fibers. It serves as a kind of fuel for colon cells—the primary part of the large intestine—but its role does not stop there. It also helps regulate inflammation and maintain the intestinal barrier, the layer that separates the intestinal contents from the underlying tissues. We can imagine this barrier as a wall: the cells are the bricks and the structures holding them together are the mortar. Butyrate nourishes the bricks and helps keep the seals efficient, supporting the wall's integrity.

Three 2026 reviews, which collect and interpret previously published studies, illustrate how this system could influence tumor development while also showing why a convincing biological rationale does not yet amount to a proven cure.

First study: does feeding the bacteria change anything?

The review by Fan and colleagues addresses a concrete question: can modifying the microbiota reduce inflammation and influence the processes that promote tumor development?

The focus is primarily on colitis-associated cancer, an inflammation of the colon. When the microbial community loses its balance, the intestinal barrier may become less effective and inflammation can persist.

The interventions studied include prebiotics, substances that nourish certain intestinal microorganisms; probiotics, live microorganisms administered to confer a health benefit; and synbiotics, which combine the two. Returning to the neighborhood analogy, prebiotics provide supplies for certain activities, whereas probiotics introduce microorganisms that may contribute to its functioning. Neither intervention alone guarantees the restoration of balance.

In animals with experimentally induced inflammation and tumors, certain interventions were associated with a lower number of tumors or smaller tumor sizes. Butyrate levels and certain components of the intestinal barrier also increased, while markers of inflammation decreased.

In humans, however, the picture is more cautious. A specific probiotic showed results comparable to an anti-inflammatory drug in keeping ulcerative colitis—an inflammatory disease of the colon—under control. This same result was not observed in Crohn's disease, another inflammatory bowel disease.

In studies on colorectal cancer, these interventions have been evaluated primarily around the time of surgery or during chemotherapy, the pharmacological treatment for cancer. The primary endpoints of interest involve infections, digestive disorders, and intestinal protection. A direct reduction in tumor mass has not been demonstrated.

Second study: it is not only who lives in the intestine that matters

Knowing the bacteria present is somewhat like having a list of businesses in a city: it is not enough to know what they produce and what effects they have on the environment.

The review by Li and colleagues focuses ␟ precisely on the products of this activity: metabolites, that is, substances produced by microorganisms. Some may support intestinal defenses, while others may promote harmful processes. The effects also depend on the quantity and the conditions under which they act.

This is the case with hydrogen sulfide. At low concentrations, it is associated with processes that support the intestinal barrier and regulate immune defenses. At high concentrations, however, it may promote damage to the cellular genetic material and protective mucus.

Dividing everything into "good" and "bad" bacteria is therefore insufficient. What matters is what they produce, how much they produce, and where.

The limitation is that many observations come from animals, laboratory-cultured cells, and organoids: small cellular structures that reproduce certain characteristics of an organ. Organoids are like scale models of a building—they allow certain aspects to be studied, but they do not reproduce everything that happens in an inhabited building. They help elucidate mechanisms rather than automatically predicting outcomes in humans.

Even introducing a new microbial community does not guarantee stable results. Data on fecal microbiota transplantation, which transfers intestinal microorganisms from a donor to a recipient, show that greater microbial diversity persists over time in only about half of patients. In short, transferring new inhabitants does not mean they will all successfully establish themselves.

Third study: butyrate is teamwork

The review by Snodgrass and Velayudhan calls for a shift in perspective. The protagonist is not a single bacterium, but a network.

Some microorganisms begin breaking down complex carbohydrates. Others use the products of this process to produce butyrate. It is a relay: the outcome depends on the handoffs between participants. If a key player is missing, adding more starting material may not suffice.

According to the review, butyrate meets approximately 60–70% of the energy requirements of the mature cells lining the colon. It is also linked to the production of protective mucus and the maintenance of intercellular "seals."

Fiber can support this network, but a community capable of transforming it is required. Antibiotics, diet, and other factors can alter the system.

The review also explores links with the brain, metabolism, and aging. These connections are interesting, but they represent associations and potential biological explanations rather than proof that increasing butyrate prevents or cures these conditions.

What this means for patients

The fundamental distinction is this: supporting the intestinal environment is not equivalent to treating a tumor. Repairing one part of the system does not mean the entire problem has been solved.

The reviews do not show that fiber, prebiotics, or probiotics eliminate existing cancer, nor that these interventions can replace oncological treatments.

Instead, they explain why the microbiota is worth studying: it can influence the intestinal barrier, inflammation, and immune defenses. However, each individual starts from a different baseline. Diet, medications, antibiotics, and disease can alter both the microbial community and how it responds.

Consequently, no single, universal solution emerges.

What we still do not know

The primary question is not merely whether an intervention increases butyrate, but whether that change confers a tangible benefit to individuals.

Measuring a substance in stool or blood provides a partial snapshot. It is akin to observing a city from a single intersection: you can see some activity, but you cannot reconstruct the entire traffic flow. Such measurements do not necessarily reflect what is happening adjacent to intestinal cells.

Similarly, a favorable biological signal does not automatically translate to fewer complications or better tumor control. It is a clue, not the final outcome.

Studies are also difficult to compare because the microorganisms used, quantities, duration, and participant characteristics vary.

Finally, observing two phenomena together does not prove that one causes the other. Finding fewer butyrate-producing bacteria in the presence of a disease does not prove the disease caused their reduction. It is like finding a wet road: without more information, we don't know whether it rained or a street-cleaning vehicle passed by.

We need studies that follow individuals over time and measure safety and actual benefits, rather than just changes in bacteria or the substances they produce.

From promise to evidence

Dietary fibers nourish networks of microorganisms, which in turn produce metabolites that can influence the intestinal environment. Reviews help reconstruct the links in this chain. It remains to be proven whether modifying it yields a tangible benefit.

The decisive question, therefore, is not only "can we alter the intestinal microbiota?", but "when does this alteration truly improve a person's life?"